Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

India Market Reflection Report Feb 2015

1,405 views

Published on

India Pharmaceutical landscape report covers Indian market overview, company watch, product performance and therapy trend.

Published in: Healthcare
  • Be the first to comment

  • Be the first to like this

India Market Reflection Report Feb 2015

  1. 1. 0 Market Reflection Report February 2015
  2. 2. 1 IPM overview Market Reflection Report February 2015 TSA IPM Trends SSA IPM Trends  IPM was valued at Rs. 89,244 crs and the retail sector was valued at Rs. 75,551 crs, both with a growth of 20% in Feb‘15 over the same month last year; CAGR growth of 11% during the period 2012-15  Multiple factors like prevalence of swine flu-H1N1, high growth in anti-infectives, respiratory and pain market with expansion of big brands, has resulted in overall robust IPM growth of 20% for the month  Indian companies continue to drive growth in the market with a growth of 22% in Feb ‘15  Cardiac and Gastro Intestinal, with respective market share of 12% and 10%, constitutes the 2nd and 3rd largest therapies MonthGrowth% Value Rs. crs Growth SPLY 89,244 79,823 72,655 65,375 7,5426,3115,8355,343 +20% +12% 20132012 20152014 75,551 67,213 61,070 55,025 6,3825,3214,9034,479 2012 +20% +12% 201520142013 MonthMAT 20 15 10 5 0 JunMayAprMarFebJan DecNovOctSepAugJul 20 15 10 5 0 Jan DecNovOctSepAugJulJunMayAprMarFeb 2013 2015 2014
  3. 3. 2 Top 150 companies snapshot Market Reflection Report February 2015 • The top 10 companies constituted 40% market share of IPM on MAT and month basis • Similarly, the top 150 companies constituted 97% market share of IPM on MAT and month basis • For the top companies, growth was driven by top 300 brands which grew by 11% for top # 1-10 companies Source: IMS Health TSA, Feb ‘15 IPM value – Rs.7,542 crs (19.5% Growth) Month Feb ‘15 IPM value – Rs.89,244 crs (11.8% Growth) MAT Feb ‘15 253 507 503 415 911 Value (Rs. Crs) Rank #101 - 150 Rank #61 - 100 Rank #41 - 60 Rank #31 - 40 Rank #21 - 30 Rank #11 - 20 1,721 Rank #1 - 10 3,020 3 7 7 6 12 23 40 % MS 11 20 25 17 22 23 17 % Gwth Value (Rs. Crs) 3,118 6,103 5,990 4,988 10,638 20,042 35,861 4 7 7 6 12 22 40 % MS 8 14 18 11 10 12 11 % Gwth
  4. 4. 3 Top companies #1-10 Market Reflection Report February 2015  TSA: Macleods, Mankind and Cipla registered remarkable growth both on MAT and month basis.  SSA: Macleods registered the highest growth both on MAT and month basis followed by Mankind Source: IMS Health TSA & SSA, Feb ‘15 256 259 261 268 367 410 469 Value (Rs. Crs) Pfizer 236 GlaxoSmithKline 241 Alkem 253 Macleods Pharma Ranbaxy Zydus Cadila Mankind Sun Cipla Abbott 18 8 20 34 10 9 27 17 21 13 % Gwth 3.1 3.2 3.4 3.4 3.4 3.5 3.6 4.9 5.4 6.2 % MS 191 199 221 221 225 226 239 306 324 403 Value (Rs. Crs) Pfizer GlaxoSmithKline Alkem Zydus Cadila Ranbaxy Macleods Pharma Mankind Sun Cipla Abbott 17 10 22 10 9 36 28 20 21 12 % Gwth 3.0 3.1 3.5 3.5 3.5 3.5 3.8 4.8 5.1 6.3 % MS Month Value (Rs. Crs) Pfizer 2,723 Macleods Pharma 2,875 GlaxoSmithKline 3,062 Alkem 3,071 Mankind 3,118 Zydus Cadila 3,163 Ranbaxy 3,233 Sun 4,242 Cipla 4,691 Abbott 5,684 9 23 4 11 18 3 6 13 20 7 % Gwth 3.1 3.2 3.4 3.4 3.5 3.5 3.6 4.8 5.3 6.4 % MS 2,501 Macleods Pharma 2,505 Zydus Cadila 2,651 Alkem 2,677 Mankind 2,779 Ranbaxy 2,826 Sun 3,515 Cipla 3,722 Abbott 4,930 Value (Rs. Crs) Pfizer 2,203 Glaxosmithkline 8 7 25 4 12 19 6 15 16 8 % Gwth 2.9 3.3 3.3 3.5 3.5 3.7 3.7 4.7 4.9 6.5 % MS MAT SSA TSA
  5. 5. 4 Top companies #11-20 Market Reflection Report February 2015 • TSA – Intas continued to register the highest growth of 39% on month basis and 20% on MAT basis among the top 11-20 companies • SSA – Additional to Intas, few companies have registered significant growth on month basis such as Aristo Pharma, Alembic and Dr Reddys Labs; while Glenmark Pharma posted significant growth on MAT basis Source: IMS Health TSA & SSA, Feb ‘15 168 168 173 174 186 212 213 Value (Rs. Crs) Alembic 132 U S V 147 Glenmark Pharma 154 Aristo Pharma Dr Reddys Labs Sanofi Emcure Torrent Pharma Intas Pharma Lupin Limited 28 15 26 27 24 21 14 26 39 21 % Gwth 1.8 2.0 2.0 2.2 2.2 2.3 2.3 2.5 2.8 2.8 % MS 119 127 132 134 143 147 150 163 180 182 Value (Rs. Crs) Alembic Sanofi U S V Glenmark Pharma Dr Reddys Labs Emcure Aristo Pharma Torrent Pharma Lupin Limited Intas Pharma 28 17 15 25 28 15 29 27 21 39 % Gwth 1.9 2.0 2.1 2.1 2.2 2.3 2.3 2.6 2.8 2.8 % MS Value (Rs. Crs) Micro Labs 1,502 U S V 1,733 Glenmark Pharma 1,756 Dr Reddys Labs 1,908 Aristo Pharma 1,980 Sanofi 2,037 Emcure 2,113 Torrent Pharma 2,134 Intas Pharma 2,330 Lupin Limited 2,549 6 9 19 12 14 3 13 9 20 15 % Gwth 1.7 1.9 2.0 2.1 2.2 2.3 2.4 2.4 2.6 2.9 % MS Value (Rs. Crs) Alembic 1,331 Glenmark Pharma 1,531 Sanofi 1,533 U S V 1,563 Dr Reddys Labs 1,615 Aristo Pharma 1,762 Emcure 1,765 Torrent Pharma 1,870 Intas Pharma 1,993 Lupin Limited 2,145 13 19 12 10 15 14 14 10 19 16 % Gwth 1.8 2.0 2.0 2.1 2.1 2.3 2.3 2.5 2.6 2.8 % MS SSA TSA MonthMAT
  6. 6. 5 Top companies #21-30 Market Reflection Report February 2015 • TSA – IPCA continued to register significant growth of 39% during the month followed by Wockhardt and Cadila Pharma • SSA – Apart from IPCA, Cadila registered significant growth of 35% during the month followed by Wockhardt at 25% Source: IMS Health TSA & SSA, Feb ‘15 74 82 93 108 109 122 126 59 61 72 Value (Rs. Crs) Franco Indian Merck Limited Msd Pharmaceutical Cadila Pharma Unichem FDC Novartis Intl. Ipca Labs Wockhardt Ltd Micro Labs 14 9 8 13 6 36 23 39 36 17 % Gwth 0.8 0.8 1.0 1.0 1.1 1.2 1.4 1.4 1.6 1.7 % MS 54 55 57 62 74 86 95 96 101 105 Value (Rs. Crs) Merck Limited Franco Indian Msd Pharmaceutical Cadila Pharma Unichem Fdc Novartis Intl. Ipca Labs Wockhardt Ltd Micro Labs 15 8 7 35 15 24 12 41 25 16 % Gwth 0.8 0.9 0.9 1.0 1.2 1.4 1.5 1.5 1.6 1.7 % MS 726 772 827 952 998 Value (Rs. Crs) Franco Indian Merck Limited Cadila Pharma Msd Pharmaceutical Unichem FDC 1,048 Wockhardt Ltd 1,241 Ipca Labs 1,276 Novartis Intl. 1,328 Alembic 1,469 11 10 12 9 8 7 11 19 3 13 % Gwth 0.8 0.9 0.9 1.1 1.1 1.2 1.4 1.4 1.5 1.7 % MS 681 684 705 753 905 971 Value (Rs. Crs) Merck Limited Franco Indian Cadila Pharma Msd Pharmaceutical Unichem Fdc Wockhardt Ltd 1,071 Ipca Labs 1,114 Novartis Intl. 1,156 Micro Labs 1,270 10 12 12 10 8 8 7 20 3 8 % Gwth 0.9 0.9 0.9 1.0 1.2 1.3 1.4 1.5 1.5 1.7 % MS SSA TSA MonthMAT
  7. 7. 6 Highlights Market Reflection Report February 2015 TSA Movers & Shakers TSA: Companies In the month of Feb’15 (in comparison to Jan’15), among the top 25 companies  Macleods Pharma has gained 3 ranks and moved to 7th position.  Mankind, Aristo Pharma and Wockhardt have gained 2 ranks each and moved to 4th, 17th and 22nd position, respectively.  Alkem, Alembic and FDC have gained 1 rank each and moved to 8th, 20th and 25th position, respectively. As per Feb’15 MAT (in comparison to Jan’15) among the top 25 companies  Abbott has maintained its top position with market share of 6.37%  Alkem has gained 1 rank and moved to 7th position. SSA Movers & Shakers SSA: Companies In the month of Feb-15 (in comparison to Jan- 15 month), among the TOP 25 companies  Abbott has maintained its top position with market share of 6.31%.  Aristo Pharma has gained 4 ranks and occupied 14th position.  Macleods Pharma has gained 3 ranks and occupied 5th position.  Wockhardt has gained 2 ranks and occupied 22nd position.  Intas and FDC have gained 1 rank each and occupied 11th and 25th position, respectively. As per Feb-15 MAT (in comparison to Jan-15 MAT), among the TOP 25 companies  Abbott has maintained its top position with market share of 6.53%.  Macleods Pharma has gained 1 rank and occupied 8th position.
  8. 8. 7 NLEM/Non-NLEM Market Reflection Report February 2015 ValueVolume  NLEM impacted drugs constituted 13% of IPM in value terms with a growth of 11.5% in Feb ‘15 over same period last year (SPLY)  The share of the non-NLEM drugs was 87% of IPM in value terms and 78% in volume terms for the month of Feb’15  The volume of NLEM drugs witnessed growth of 8% in Feb ’15 over the same period last year. Source: IMS Health TSA, Feb ‘15 SPLY Previous month Feb '14 Feb '15 Value Growth (%) Jan '14 Feb '15 Value Growth (%) Rs. (crs) Rs. (crs) Rs. (crs) Rs. (crs) NLEM 909.1 1014.0 11.5 975.2 1014.0 4.0 Non-NLEM 5402.3 6528.3 20.8 6446.7 6528.3 1.3 IPM 6311.5 7542.3 19.5 7421.9 7542.3 1.6 SPLY Previous month Feb '14 Feb '15 Volume Growth (% ) Jan '14 Feb '15 Volume Growth (%)Units (‘000) Units (‘000) Units (‘000) Units (‘000) NLEM 356471 384836 8.0 367813 384836 4.6 Non-NLEM 1180693 1343376 13.8 1296134 1343376 3.6 IPM 1537164 1728211 12.4 1663947 1728211 3.9
  9. 9. 8 Indian /MNC trends Market Reflection Report February 2015 • Indian companies continue to capture the larger share of IPM at 74% during the month with a significant growth of 22% over Feb’14 • With 3 MNCs represented in the top 10 companies, the share of MNCs constituted 26% of IPM Source: IMS Health TSA, Feb ‘15 0 5 10 15 20 25 % Gwth over same month last year MNC Indian IPM Feb ’15Jan ’15Dec ’14Nov ’14Oct ’14Sep ’14Aug ’14Jul ’14Jun ’14May ’14Apr ’14Mar ’14 0 1,000 2,000 3,000 4,000 5,000 6,000 7,000 8,000 Value (Rs. Crs) MNC Indian IPM Feb ’15Jan ’15Dec ’14Nov ’14Oct ’14Sep ’14Aug ’14Jul ’14Jun ’14May ’14Apr ’14Mar ’14 MonthGrowthValue
  10. 10. 9 Acute/Chronic trends Market Reflection Report February 2015  Acute therapies continue to dominate the market accounting for 70% of the market during the month  Chronic therapies registered growth of 18%, while acute therapies attained significant growth of 20% over Feb’14  Cough preparation was the highest selling therapeutic subgroup in value terms with significant growth of 35% on month basis Source: IMS Health TSA, Feb ‘15 5 10 15 20 25 Feb ’15Jan ’15Dec ’14Nov ’14Oct ’14Sep ’14Aug ’14Jul ’14Jun ’14May ’14Apr ’14Mar ’14 9584 109116 176 Amoxy. & Clav. SolidsFood SupplementsGlim+MetforminDPP4 inhibitors & CombCough Preps Ethical 34.93 27.23 20.09 -5.38 27.58 9 18 23 Franco Indian Wockhardt Ltd Glenmark Pharma 18 26 28 U S V Novartis Intl. MSD Pharma 10 10 23 Lupin Limited Sun U S V 12 13 14 Nutricia Internat Abbott Apex 15 15 17 Mankind Alkem GlaxoSmithKline Top5TC4sTop3Cos.inTC4 Growth (%) Value (Rs. Crs) Value (Rs. Crs) Growth(%) Value (Rs. Crs) Value (Rs. Crs) Value (Rs. Crs) Value (Rs. Crs) ChronicIPM Acute
  11. 11. 10 Top 40 brands Market Reflection Report February 2015  Alburel (Reliance Life Sciences) registered outstanding growth of 118% during the month  Being a new launch, Biovac V (Wockhardt) has registered astounding growth and attained its position in top 40 brands  Magnex (Pfizer), Prevenar-13 (Pfizer), Panderm+ (Macleods), Thyronorm (Abbott) and Electral (FDC) posted impressive growth greater than 50% in Feb ’15 over the same month last year 22 22 22 23 30 30 38 19 20 22 Value (Rs. Crs) Phensedyl Cough Monocef Prevenar-13 Clavam Panderm+ Thyronorm Glycomet-GP Corex Augmentin Mixtard -9 29 70 24 60 56 22 16 35 14 % Gwth % MS 0.26 0.27 0.29 0.29 0.30 0.30 0.31 0.40 0.40 0.50 15 15 15 15 15 16 16 16 16 15 Value (Rs. Crs) Zifi Becosules Azithral Budecort Shelcal Alburel Moxikind-CV Biovac V Foracort Liv-52 35 16 38 41 34 30 23 8 % Gwth 999 118 % MS 0.20 0.20 0.20 0.20 0.20 0.20 0.21 0.21 0.22 0.22 16 17 17 18 18 18 18 18 18 19 Volini Novomix Voveran Value (Rs. Crs) Electral Spasmo-Proxyvon + Lantus Dexorange Galvus Met Betadine Janumet 56 3 20 7 16 12 29 1 23 30 % Gwth % MS 0.22 0.23 0.23 0.23 0.23 0.23 0.24 0.24 0.24 0.25 13 13 13 13 13 14 14 14 14 14 Value (Rs. Crs) Synflorix Seroflo Zinetac Magnex Zincovit Duphaston Taxim-o Aciloc Calpol Pan 50 14 5 81 7 17 15 28 35 13 % Gwth 0.17 % MS 0.17 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.19 Top1-10Top11-20 Top21-30Top31-40 Source: IMS Health TSA, Feb ‘15
  12. 12. 11 Star Brands of the month Market Reflection Report February 2015 TSA Movers & Shakers TSA: Products Among the Top 25 products as per Feb’15 month (in comparison to Jan’15 month)  Mixtard (Abbott) is the No 1 brand.  Alburel (Reliance Life Sciences) has gained 29 ranks to occupy 25th position.  Monocef (Aristo Pharmaceuticals) has gained 12 ranks to occupy 9th position.  Dexorange (Franco-Indian) and Moxikind CV (Mankind) has gained 9 ranks to occupy 17th and 24th position, respectively.  Panderm+ (Macleods) and Clavam (Alkem) has gained 6 ranks to occupy 6th and 7th position, respectively.  Thyronorm (Abbott), Betadine (Win Medicare), Electral (FDC) and Liv-52 (Himalaya) have gained 2 ranks each to occupy 5th ,15th, 20th and 21st position, respectively.  Augmentin (GSK) and Volini (Ranbaxy) have gained 1 rank each to occupy 2nd and 13th position, respectively Among the Top 25 products as per Feb’15 MAT (in comparison to Jan’15 MAT)  Mixtard (Abbott) is the No 1 brand.  Panderm + (Macleods) has gained 3 ranks to occupy 21st position.  Prevenar-13 (Pfizer) has gained 2 ranks to occupy 9th position.  Volini (Ranbaxy), Dexorange (Franco-Indian), Thyronorm (Abbott), Novomix (Abbott), Janumet (MSD) and Shelcal (Torrent Pharma) have gained 1 rank each to occupy 6th, 7th, 8th,14th, 17th and 24th position, respectively.
  13. 13. 12 Vaccines 164 Others 235 Gynaec. 416 Neuro / CNS 454 Derma 462 Vitamins / Minerals / Nutrients 527 Anti Diabetic 583 Pain / Analgesics 594 Respiratory 695 Gastro Intestinal 771 Cardiac 873 Anti-infectives 1,111 IPM 7,542 6 6 6 2 3 7 8 8 9 10 12 15 100 15 16 42 23 14 19 21 20 24 19 16 23 20 1 1 -4 -3 -5 1 -5 3 8 2 -5 15 2 Gwth % (SPLY) Gwth% (Prev. Mth) Therapy trends • Vaccines recorded significant value growth of 42% as of MAT Feb ’15 • Anti-infectives constitute the largest market share of 15%, with significant growth both on month and MAT basis Source: IMS Health TSA, Feb ‘15 Market Reflection Report February 2015 Value (Rs Crs) MS %
  14. 14. 13 Top Therapy Trends Market Reflection Report February 2015 Source: IMS Health TSA, Feb ‘15 29 30 33 33 42 44 48 54 57 95 Value (Rs. Crs) Amikacin Cefuroxime Oral Solids Meropenem Piperacillin+Tazobactam Cefpodoxime Solids Azithromycin Oral Solids Amoxy. & Clav. Liquids Cefixime Oral Sol. Ceftriaxone Injectabls Amoxy. & Clav. Solids 28 16 7 22 30 39 16 30 28 27 % Gwth (SPLY) 18 24 29 29 31 32 33 40 43 66 Value (Rs. Crs) Losartan+ Hydrochlorthiaz Amlodipine+Telmisartan Amlodipine Enoxaparin Telmisartan + HCT Atenolol+Amlodipine Metoprolol Telmisartan Rosuvastatin Atorvastatin 5 26 9 6 11 15 12 22 23 14 % Gwth (SPLY) Anti-Infective 21 22 23 24 27 29 38 39 43 47 Value (Rs. Crs) Digest. Inc. Enzyme Liqui Rabeprazole Omepraz.+ Domperid. Antacid+Antiflatu.Liq Others Oral Electrolytes Pantoprazole Solids Ranitidine Oral Solids Rabepra.+ Domperid. Pantopr.+ Domperid. 26 13 14 20 23 47 15 14 24 25 % Gwth (SPLY) 14 15 18 21 30 31 40 42 67 176 Value (Rs. Crs) Levocetirizine Salbutamol+Ipratropium Budesonide Salmeterol+Fluticasone Cold Prep. Solids Formoteral+Budesonide Levocetiriz.+Montelu Sold Cold Prep. Liquids Codeine And Comb. Cough Prep. Ethicals 21 28 42 17 24 23 26 23 8 35 % Gwth (SPLY) Cardiac GI Respiratory • Oral Electrolytes, Budesonide, Amikacin and Cough Prep. Ethicals registered significant growth greater than 30% over the same period last year
  15. 15. 14 Glossary Market Reflection Report February 2015 Abbreviation Description/Definition IPM Indian Pharmaceutical Market MAT Moving Annual Total CAGR Compound Annual Growth Rate TSA Total Sales Audit SSA Secondary Sales Audit Gwth Growth MS Market Share Rs Rupees NLEM National List of Essential Medicines SPLY Same Period Late Year MNC Multi-National Company DPP Dipeptidyl Peptidase 4 TC Therapeutic Category Crore / crs 10 million
  16. 16. 15 About IMS Health World’s leading provider of healthcare consulting, technology, and informatics  Founded in 1954  Operates in over 100 countries; employs 10,000+ people world wide  Data from 100,000 suppliers and insights of more than 40 billion healthcare transactions  1200+ experts resources, 3000+ service resources and 5000+ clients  Operational in India for more than 11 years, with over 2000 employees with offices in Gurgaon, Mumbai, Delhi & Bangalore PUBLIC HEALTH  Policyreformsand advocacy  Enabling evidence based publichealth decisions  Health infrastructure development  Health resourcesplanning and allocation  Monitoring &evaluation  Designing and implementation support  Strengthening health caresupply chain  Enabling TechnologySolutions  Product& Portfolio strategy  Entry& Growth Strategy  Brand and Commercial Strategy  Pricing and marketaccess  Launch and commercial Excellence  Performance management  Transaction AdvisoryServicesand Due Diligence  Drug salesdatabase(global and local)  Census - Physicians,Chemists, Hospitals,Doctor, etc PHARMA & ALLIED HEALTH  Networkexpansion and management  Doctorselection  Pharma &Providerengagement strategy  Diseasemanagement  Claimsdatabase  Claimsanalytics– benchmarksand costs  Patientlevel information  Health technologyassessment PAYERS PROVIDERS  Providerdatabases  Hospital performance transformation programs  Performance benchmarking  Expansion &Growth strategy  Feasibilityanalysisand businessplan development  Brownfield hospital acquisition  Financial modeling,funding modalities and transaction advisory  BI Solutionsforhospitals OUR SERVICE OFFERINGS 95 process patents worldwide in life sciences processes Ranked 2nd Life Science Technology Vendors for 2013 (IT Services) by IDC World’s most admired companies FORTUNE Magazine 2008 and 2010 PHARMA AND LIFE-SCIENCES
  17. 17. 16 Disclaimer  The analyses, their interpretation, and related information contained herein are made and provided subject to the assumptions, methodologies, caveats, and variables described in this report and are based on third party sources and data reasonably believed to be reliable. No warranty is made as to the completeness or accuracy of such third party sources or data.  As with any attempt to estimate future events, the forecasts, projections, conclusions, and other information included herein are subject to certain risks and uncertainties, and are not to be considered guarantees of any particular outcome.  It should neither be regarded as comprehensive nor sufficient for making decisions, nor should it be used in place of professional advice. IMS Health accepts no responsibility for any loss arising from any action taken or not taken by anyone using this material.  All reproduction rights, quotations, broadcasting, publications reserved. No part of this presentation may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without express written consent of IMS HEALTH.  ©2015 IMS Health Incorporated and its affiliates. All rights reserved. Trademarks are registered in the United States and in various other countries.

×